560 related articles for article (PubMed ID: 30647848)
21. Targeting SWI/SNF ATPases in H3.3K27M diffuse intrinsic pontine gliomas.
Mota M; Sweha SR; Pun M; Natarajan SK; Ding Y; Chung C; Hawes D; Yang F; Judkins AR; Samajdar S; Cao X; Xiao L; Parolia A; Chinnaiyan AM; Venneti S
Proc Natl Acad Sci U S A; 2023 May; 120(18):e2221175120. PubMed ID: 37094128
[TBL] [Abstract][Full Text] [Related]
22. Histone H3K27M Mutation in Brain Tumors.
El-Hashash AHK
Adv Exp Med Biol; 2021; 1283():43-52. PubMed ID: 33155136
[TBL] [Abstract][Full Text] [Related]
23. Detection of H3K27M mutation in cases of brain stem subependymoma.
Yao K; Duan Z; Wang Y; Zhang M; Fan T; Wu B; Qi X
Hum Pathol; 2019 Feb; 84():262-269. PubMed ID: 30389438
[TBL] [Abstract][Full Text] [Related]
24. Epigenetic and Metabolic Changes in Diffuse Intrinsic Pontine Glioma.
Park J; Chung C
Brain Tumor Res Treat; 2023 Apr; 11(2):86-93. PubMed ID: 37151150
[TBL] [Abstract][Full Text] [Related]
25. H3.3 K27M depletion increases differentiation and extends latency of diffuse intrinsic pontine glioma growth in vivo.
Silveira AB; Kasper LH; Fan Y; Jin H; Wu G; Shaw TI; Zhu X; Larson JD; Easton J; Shao Y; Yergeau DA; Rosencrance C; Boggs K; Rusch MC; Ding L; Zhang J; Finkelstein D; Noyes RM; Russell BL; Xu B; Broniscer A; Wetmore C; Pounds SB; Ellison DW; Zhang J; Baker SJ
Acta Neuropathol; 2019 Apr; 137(4):637-655. PubMed ID: 30770999
[TBL] [Abstract][Full Text] [Related]
26. Clinical, imaging, and molecular analysis of pediatric pontine tumors lacking characteristic imaging features of DIPG.
Chiang J; Diaz AK; Makepeace L; Li X; Han Y; Li Y; Klimo P; Boop FA; Baker SJ; Gajjar A; Merchant TE; Ellison DW; Broniscer A; Patay Z; Tinkle CL
Acta Neuropathol Commun; 2020 Apr; 8(1):57. PubMed ID: 32326973
[TBL] [Abstract][Full Text] [Related]
27. Impact of the H3K27M mutation on survival in pediatric high-grade glioma: a systematic review and meta-analysis.
Lu VM; Alvi MA; McDonald KL; Daniels DJ
J Neurosurg Pediatr; 2018 Nov; 23(3):308-316. PubMed ID: 30544362
[TBL] [Abstract][Full Text] [Related]
28. Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201.
Chi AS; Tarapore RS; Hall MD; Shonka N; Gardner S; Umemura Y; Sumrall A; Khatib Z; Mueller S; Kline C; Zaky W; Khatua S; Weathers SP; Odia Y; Niazi TN; Daghistani D; Cherrick I; Korones D; Karajannis MA; Kong XT; Minturn J; Waanders A; Arillaga-Romany I; Batchelor T; Wen PY; Merdinger K; Schalop L; Stogniew M; Allen JE; Oster W; Mehta MP
J Neurooncol; 2019 Oct; 145(1):97-105. PubMed ID: 31456142
[TBL] [Abstract][Full Text] [Related]
29. H3K27me3 in Diffuse Midline Glioma and Epithelial Ovarian Cancer: Opposing Epigenetic Changes Leading to the Same Poor Outcomes.
Day CA; Hinchcliffe EH; Robinson JP
Cells; 2022 Oct; 11(21):. PubMed ID: 36359771
[TBL] [Abstract][Full Text] [Related]
30. Identification of prognostic markers in diffuse midline gliomas H3K27M-mutant.
Dufour C; Perbet R; Leblond P; Vasseur R; Stechly L; Pierache A; Reyns N; Touzet G; Le Rhun E; Vinchon M; Maurage CA; Escande F; Renaud F
Brain Pathol; 2020 Jan; 30(1):179-190. PubMed ID: 31348837
[TBL] [Abstract][Full Text] [Related]
31. Differentiation between spinal cord diffuse midline glioma with histone H3 K27M mutation and wild type: comparative magnetic resonance imaging.
Jung JS; Choi YS; Ahn SS; Yi S; Kim SH; Lee SK
Neuroradiology; 2019 Mar; 61(3):313-322. PubMed ID: 30662997
[TBL] [Abstract][Full Text] [Related]
32. Histone Variant and Cell Context Determine H3K27M Reprogramming of the Enhancer Landscape and Oncogenic State.
Nagaraja S; Quezada MA; Gillespie SM; Arzt M; Lennon JJ; Woo PJ; Hovestadt V; Kambhampati M; Filbin MG; Suva ML; Nazarian J; Monje M
Mol Cell; 2019 Dec; 76(6):965-980.e12. PubMed ID: 31588023
[TBL] [Abstract][Full Text] [Related]
33. Histone tail analysis reveals H3K36me2 and H4K16ac as epigenetic signatures of diffuse intrinsic pontine glioma.
An S; Camarillo JM; Huang TY; Li D; Morris JA; Zoltek MA; Qi J; Behbahani M; Kambhampati M; Kelleher NL; Nazarian J; Thomas PM; Saratsis AM
J Exp Clin Cancer Res; 2020 Nov; 39(1):261. PubMed ID: 33239043
[TBL] [Abstract][Full Text] [Related]
34. Oncohistone Mutations in Diffuse Intrinsic Pontine Glioma.
Zhang X; Zhang Z
Trends Cancer; 2019 Dec; 5(12):799-808. PubMed ID: 31813457
[TBL] [Abstract][Full Text] [Related]
35. Incidence and clinicopathologic features of H3 K27M mutations in adults with radiographically-determined midline gliomas.
Schreck KC; Ranjan S; Skorupan N; Bettegowda C; Eberhart CG; Ames HM; Holdhoff M
J Neurooncol; 2019 May; 143(1):87-93. PubMed ID: 30864101
[TBL] [Abstract][Full Text] [Related]
36. H3 K27M-altered glioma and diffuse intrinsic pontine glioma: Semi-systematic review of treatment landscape and future directions.
van den Bent M; Saratsis AM; Geurts M; Franceschi E
Neuro Oncol; 2024 May; 26(Supplement_2):S110-S124. PubMed ID: 38102230
[TBL] [Abstract][Full Text] [Related]
37. Four methods to analyze H3K27M mutation in diffuse midline gliomas.
Zhao H; Fang X; Xue B
Pathol Res Pract; 2020 Sep; 216(9):153065. PubMed ID: 32825938
[TBL] [Abstract][Full Text] [Related]
38. Mosaic Pattern of H3 K27M-Mutant Protein Expression in a Diffuse Midline Glioma-A Diagnostic Dilemma for the Pathologist.
Narasimhaiah D; Thomas B; Abraham M; Poyuran R
J Neurosci Rural Pract; 2021 Jul; 12(3):596-598. PubMed ID: 34295118
[TBL] [Abstract][Full Text] [Related]
39. Oncohistones and disrupted development in pediatric-type diffuse high-grade glioma.
Ocasio JK; Budd KM; Roach JT; Andrews JM; Baker SJ
Cancer Metastasis Rev; 2023 Jun; 42(2):367-388. PubMed ID: 37119408
[TBL] [Abstract][Full Text] [Related]
40. Diffuse midline gliomas with histone H3-K27M mutation: A rare case with PNET-like appearance and neuropil-like islands.
Gao Y; Feng YY; Yu JH; Li QC; Qiu XS; Wang EH
Neuropathology; 2018 Apr; 38(2):165-170. PubMed ID: 28880421
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
